Friday, 29 March 2024


APRINOIA announces NMPA approval to initiate Ph 3 clinical trial

28 October 2020 | News

The objective of Phase 3 clinical trial is to evaluate the safety and effectiveness of [18F]-APN-1607

Image source: Shutterstock

Image source: Shutterstock

APRINOIA Therapeutics advancing a pipeline featuring diagnostic and therapeutic programs, collectively targeting brain disorders has recently announced that China National Medical Products Administration (NMPA) had approved to initiate Phase 3 clinical trial to evaluate APRINOIA's positron emission tomography (PET) imaging tracer, [18F]-APN-1607, targeting abnormal tau protein aggregates in brains of patients of cognitive impairment.

[18F]-APN-1607 is a new generation tau PET imaging tracer with improved selectivity and off-target binding profiles. It is designed to specifically recognize tau proteins in their pathological aggregated states, but not normal physiological ones.

The objective of Phase 3 clinical trial is to evaluate the safety and effectiveness of [18F]-APN-1607 to differentiate patients with Mild Cognitive Impairment (MCI) and different stages of Alzheimer's disease (AD) from healthy subjects. The proposed trial will enroll approximately 230 subjects with all receiving [18F]-APN-1607.

Pathological tau proteins are associated with neurodegeneration in AD, as well as in other tau-related brain disorders, a.k.a. tauopathies, including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Tau abnormality has been recognized as a key biomarker to characterize those tauopathies. [18F]-APN-1607 could quantify and visualize tau burden and distribution in all those tauopathies, offering broader clinical utilities.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account